6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
Evidence review of bremelanotide (Vyleesi) efficacy differences in Hispanic / Latino populations, covering RECONNECT trial subgroup data, MC4R pharmacogenomics, metabolic confounders, and practical dosing guidance.
Evidence-based review of bremelanotide (Vyleesi) efficacy in South Asian women, including MC4R pharmacogenomics, cardiovascular screening at lower BMI thresholds, and ethnicity-stratified trial gaps.
Evidence-based review of how bremelanotide (Vyleesi) safety, pharmacogenomics, and dosing considerations differ for South Asian women, including cardiovascular monitoring and melanocortin receptor variability.
A clinical deep-dive into bremelanotide (Vyleesi) safety and efficacy differences in East Asian women, covering CYP2C19/CYP2D6 pharmacogenomics, BMI-adjusted dosing considerations, and what the RECONNECT trial data reveal about ethnicity-stratified outcomes.
A deep dive into bremelanotide (Vyleesi) pharmacogenomics, dosing, and safety considerations specific to Hispanic and Latino women, with ethnicity-stratified data, CYP variant analysis, and RECONNECT trial subgroup findings.
A clinical review of bremelanotide (Vyleesi) pharmacokinetics, pharmacogenomics, and cardiovascular considerations specific to South Asian patients, including practical dosing guidance reviewed by HealthRX.com physicians.